These findings led the authors to propose that miR-494 synergistically suppresses GIST when expressed by targeting both survivin and KIT. These KIT-targeting miRNAs as well as the ETV1-targeting miR-17 and miR-20a [88] may be of therapeutic value, particularly in drug-resistant diseases in which GISTs still rely on KIT signaling. Here, ETV1 is linked to gastrointestinal stromal tumor.